Seres Therapeutics, Inc.
Seres Therapeutics, Inc. (MCRB) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
mcrb · stock forecast · 18 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 18 Wall Street analysts in the past 3 months
Buy
18 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$1.25
Consensus
$1.25
-80.1% upside
Low
$1.25
Median: $1.25 · Last Close: $6.28
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $5.97 | ↓ 4.91% |
1-day model range: $5.88–$6.06. Peak: $6.06 (-4.91%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · MCRB · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-13 | Canaccord Genuity | Maintains | Buy→Buy |
| 2025-09-24 | Canaccord Genuity | Maintains | Buy→Buy |
| 2025-05-08 | Chardan Capital | Downgrade ↓ | Buy→Neutral |
| 2025-03-20 | Chardan Capital | Maintains | Buy→Buy |
| 2025-03-14 | Goldman Sachs | Maintains | Sell→Sell |
| 2024-11-14 | Canaccord Genuity | Maintains | Buy→Buy |
| 2024-11-13 | Chardan Capital | Maintains | Buy→Buy |
| 2024-10-24 | JP Morgan | Downgrade ↓ | Neutral→Underweight |
| 2024-09-13 | Canaccord Genuity | Maintains | Buy→Buy |
| 2024-08-14 | Canaccord Genuity | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Seres Therapeutics, Inc. (MCRB) stock. Of the recent 62 rating actions, 4 were upgrades and 9 were downgrades. 18 analysts currently cover MCRB.
Analyst Recommendation Trends
MCRB analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 62.8% YoY
Revenue Next Year
$1M
↑ 168.5% YoY
EPS This Year
$0.26
EPS Next Year
$-9.19
↓ 3589.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast MCRB EPS of $0.26 for the current fiscal year, based on estimates from 1 analysts. The MCRB revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The MCRB stock forecast is supported by two independent data sources: analyst consensus ratings from 18 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MCRB price target is $1.25 (-80.1% upside), with an analyst consensus of Buy.
The MCRB short-term stock prediction for tomorrow is $5.97 (-4.91%).
Seres Therapeutics, Inc. trades on NASDAQ under the ticker MCRB. The MCRB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 61% of covering analysts.
Frequently asked questions
MCRB forecast · 8 questionsAccording to 18 Wall Street analysts, the average 12-month MCRB price target is $1.25, with a high forecast of $1.25 and a low of $1.25. The median price target is shown in the chart above when available. This implies -80.1% potential upside from the current price of $6.28.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.